

# Global APOL1 Mediated Kidney Disease Market Insights, Forecast to 2029

<https://marketpublishers.com/r/G1DF96B43EBBEN.html>

Date: December 2023

Pages: 95

Price: US\$ 4,900.00 (Single User License)

ID: G1DF96B43EBBEN

## Abstracts

This report presents an overview of global market for APOL1 Mediated Kidney Disease market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of APOL1 Mediated Kidney Disease, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for APOL1 Mediated Kidney Disease, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the APOL1 Mediated Kidney Disease revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global APOL1 Mediated Kidney Disease market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for APOL1 Mediated Kidney Disease revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Vertex

Pharmaceuticals, Ionis Pharmaceuticals, Travere Therapeutics, ChemoCentryx, ZyVersa Therapeutics, GlaxoSmithKline, Novartis and Teva Pharmaceuticals, etc.

### By Company

Vertex Pharmaceuticals

Ionis Pharmaceuticals

Travere Therapeutics

ChemoCentryx

ZyVersa Therapeutics

GlaxoSmithKline

Novartis

Teva Pharmaceuticals

### Segment by Type

Small Molecule

Gene Modification

Nucleic Acid Therapies

Others

### Segment by Application

Chronic Kidney Disease

End Stage Kidney Disease

## By Region

### North America

United States

Canada

### Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

### Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

## Latin America

Mexico

Brazil

Rest of Latin America

## Middle East, Africa, and Latin America

Turkey

Saudi Arabia

UAE

Rest of MEA

## Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of APOL1 Mediated Kidney Disease in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of APOL1 Mediated Kidney Disease companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America by type, by application and by country, revenue for each segment.

Chapter 7: Europe by type, by application and by country, revenue for each segment.

Chapter 8: China by type and by application revenue for each segment.

Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, APOL1 Mediated Kidney Disease revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions

## Contents

### 1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Market Analysis by Type
  - 1.2.1 Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
  - 1.2.2 Small Molecule
  - 1.2.3 Gene Modification
  - 1.2.4 Nucleic Acid Therapies
  - 1.2.5 Others
- 1.3 Market by Application
  - 1.3.1 Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
  - 1.3.2 Chronic Kidney Disease
  - 1.3.3 End Stage Kidney Disease
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered

### 2 GLOBAL GROWTH TRENDS

- 2.1 Global APOL1 Mediated Kidney Disease Market Perspective (2018-2029)
- 2.2 Global APOL1 Mediated Kidney Disease Growth Trends by Region
  - 2.2.1 APOL1 Mediated Kidney Disease Market Size by Region: 2018 VS 2022 VS 2029
  - 2.2.2 APOL1 Mediated Kidney Disease Historic Market Size by Region (2018-2023)
  - 2.2.3 APOL1 Mediated Kidney Disease Forecasted Market Size by Region (2024-2029)
- 2.3 APOL1 Mediated Kidney Disease Market Dynamics
  - 2.3.1 APOL1 Mediated Kidney Disease Industry Trends
  - 2.3.2 APOL1 Mediated Kidney Disease Market Drivers
  - 2.3.3 APOL1 Mediated Kidney Disease Market Challenges
  - 2.3.4 APOL1 Mediated Kidney Disease Market Restraints

### 3 COMPETITION LANDSCAPE BY KEY PLAYERS

- 3.1 Global Revenue APOL1 Mediated Kidney Disease by Players

- 3.1.1 Global APOL1 Mediated Kidney Disease Revenue by Players (2018-2023)
- 3.1.2 Global APOL1 Mediated Kidney Disease Revenue Market Share by Players (2018-2023)
- 3.2 Global APOL1 Mediated Kidney Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Global Key Players of APOL1 Mediated Kidney Disease, Ranking by Revenue, 2021 VS 2022 VS 2023
- 3.4 Global APOL1 Mediated Kidney Disease Market Concentration Ratio
  - 3.4.1 Global APOL1 Mediated Kidney Disease Market Concentration Ratio (CR5 and HHI)
  - 3.4.2 Global Top 10 and Top 5 Companies by APOL1 Mediated Kidney Disease Revenue in 2022
- 3.5 Global Key Players of APOL1 Mediated Kidney Disease Head office and Area Served
- 3.6 Global Key Players of APOL1 Mediated Kidney Disease, Product and Application
- 3.7 Global Key Players of APOL1 Mediated Kidney Disease, Date of Enter into This Industry
- 3.8 Mergers & Acquisitions, Expansion Plans

#### **4 APOL1 MEDIATED KIDNEY DISEASE BREAKDOWN DATA BY TYPE**

- 4.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Type (2018-2023)
- 4.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Type (2024-2029)

#### **5 APOL1 MEDIATED KIDNEY DISEASE BREAKDOWN DATA BY APPLICATION**

- 5.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Application (2018-2023)
- 5.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Application (2024-2029)

#### **6 NORTH AMERICA**

- 6.1 North America APOL1 Mediated Kidney Disease Market Size (2018-2029)
- 6.2 North America APOL1 Mediated Kidney Disease Market Size by Type
  - 6.2.1 North America APOL1 Mediated Kidney Disease Market Size by Type (2018-2023)
  - 6.2.2 North America APOL1 Mediated Kidney Disease Market Size by Type

(2024-2029)

6.2.3 North America APOL1 Mediated Kidney Disease Market Share by Type

(2018-2029)

6.3 North America APOL1 Mediated Kidney Disease Market Size by Application

6.3.1 North America APOL1 Mediated Kidney Disease Market Size by Application

(2018-2023)

6.3.2 North America APOL1 Mediated Kidney Disease Market Size by Application

(2024-2029)

6.3.3 North America APOL1 Mediated Kidney Disease Market Share by Application

(2018-2029)

6.4 North America APOL1 Mediated Kidney Disease Market Size by Country

6.4.1 North America APOL1 Mediated Kidney Disease Market Size by Country: 2018

VS 2022 VS 2029

6.4.2 North America APOL1 Mediated Kidney Disease Market Size by Country

(2018-2023)

6.4.3 North America APOL1 Mediated Kidney Disease Market Size by Country

(2024-2029)

6.4.4 United States

6.4.5 Canada

## **7 EUROPE**

7.1 Europe APOL1 Mediated Kidney Disease Market Size (2018-2029)

7.2 Europe APOL1 Mediated Kidney Disease Market Size by Type

7.2.1 Europe APOL1 Mediated Kidney Disease Market Size by Type (2018-2023)

7.2.2 Europe APOL1 Mediated Kidney Disease Market Size by Type (2024-2029)

7.2.3 Europe APOL1 Mediated Kidney Disease Market Share by Type (2018-2029)

7.3 Europe APOL1 Mediated Kidney Disease Market Size by Application

7.3.1 Europe APOL1 Mediated Kidney Disease Market Size by Application

(2018-2023)

7.3.2 Europe APOL1 Mediated Kidney Disease Market Size by Application

(2024-2029)

7.3.3 Europe APOL1 Mediated Kidney Disease Market Share by Application

(2018-2029)

7.4 Europe APOL1 Mediated Kidney Disease Market Size by Country

7.4.1 Europe APOL1 Mediated Kidney Disease Market Size by Country: 2018 VS 2022

VS 2029

7.4.2 Europe APOL1 Mediated Kidney Disease Market Size by Country (2018-2023)

7.4.3 Europe APOL1 Mediated Kidney Disease Market Size by Country (2024-2029)



7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

## **8 CHINA**

8.1 China APOL1 Mediated Kidney Disease Market Size (2018-2029)

8.2 China APOL1 Mediated Kidney Disease Market Size by Type

8.2.1 China APOL1 Mediated Kidney Disease Market Size by Type (2018-2023)

8.2.2 China APOL1 Mediated Kidney Disease Market Size by Type (2024-2029)

8.2.3 China APOL1 Mediated Kidney Disease Market Share by Type (2018-2029)

8.3 China APOL1 Mediated Kidney Disease Market Size by Application

8.3.1 China APOL1 Mediated Kidney Disease Market Size by Application (2018-2023)

8.3.2 China APOL1 Mediated Kidney Disease Market Size by Application (2024-2029)

8.3.3 China APOL1 Mediated Kidney Disease Market Share by Application  
(2018-2029)

## **9 ASIA (EXCLUDING CHINA)**

9.1 Asia APOL1 Mediated Kidney Disease Market Size (2018-2029)

9.2 Asia APOL1 Mediated Kidney Disease Market Size by Type

9.2.1 Asia APOL1 Mediated Kidney Disease Market Size by Type (2018-2023)

9.2.2 Asia APOL1 Mediated Kidney Disease Market Size by Type (2024-2029)

9.2.3 Asia APOL1 Mediated Kidney Disease Market Share by Type (2018-2029)

9.3 Asia APOL1 Mediated Kidney Disease Market Size by Application

9.3.1 Asia APOL1 Mediated Kidney Disease Market Size by Application (2018-2023)

9.3.2 Asia APOL1 Mediated Kidney Disease Market Size by Application (2024-2029)

9.3.3 Asia APOL1 Mediated Kidney Disease Market Share by Application (2018-2029)

9.4 Asia APOL1 Mediated Kidney Disease Market Size by Region

9.4.1 Asia APOL1 Mediated Kidney Disease Market Size by Region: 2018 VS 2022 VS  
2029

9.4.2 Asia APOL1 Mediated Kidney Disease Market Size by Region (2018-2023)

9.4.3 Asia APOL1 Mediated Kidney Disease Market Size by Region (2024-2029)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

## **10 MIDDLE EAST, AFRICA, AND LATIN AMERICA**

10.1 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size (2018-2029)

10.2 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Type

10.2.1 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Type (2018-2023)

10.2.2 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Type (2024-2029)

10.2.3 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Share by Type (2018-2029)

10.3 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Application

10.3.1 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Application (2018-2023)

10.3.2 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Application (2024-2029)

10.3.3 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Share by Application (2018-2029)

10.4 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Country

10.4.1 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Country: 2018 VS 2022 VS 2029

10.4.2 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Country (2018-2023)

10.4.3 Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Country (2024-2029)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

## 11 KEY PLAYERS PROFILES

### 11.1 Vertex Pharmaceuticals

11.1.1 Vertex Pharmaceuticals Company Details

11.1.2 Vertex Pharmaceuticals Business Overview

11.1.3 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Introduction

11.1.4 Vertex Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)

11.1.5 Vertex Pharmaceuticals Recent Developments

### 11.2 Ionis Pharmaceuticals

11.2.1 Ionis Pharmaceuticals Company Details

11.2.2 Ionis Pharmaceuticals Business Overview

11.2.3 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Introduction

11.2.4 Ionis Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)

11.2.5 Ionis Pharmaceuticals Recent Developments

### 11.3 Travele Therapeutics

11.3.1 Travele Therapeutics Company Details

11.3.2 Travele Therapeutics Business Overview

11.3.3 Travele Therapeutics APOL1 Mediated Kidney Disease Introduction

11.3.4 Travele Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)

11.3.5 Travele Therapeutics Recent Developments

### 11.4 ChemoCentryx

11.4.1 ChemoCentryx Company Details

11.4.2 ChemoCentryx Business Overview

11.4.3 ChemoCentryx APOL1 Mediated Kidney Disease Introduction

11.4.4 ChemoCentryx Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)

11.4.5 ChemoCentryx Recent Developments

### 11.5 ZyVersa Therapeutics

11.5.1 ZyVersa Therapeutics Company Details

11.5.2 ZyVersa Therapeutics Business Overview

11.5.3 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Introduction

11.5.4 ZyVersa Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)

11.5.5 ZyVersa Therapeutics Recent Developments

### 11.6 GlaxoSmithKline

11.6.1 GlaxoSmithKline Company Details

- 11.6.2 GlaxoSmithKline Business Overview
- 11.6.3 GlaxoSmithKline APOL1 Mediated Kidney Disease Introduction
- 11.6.4 GlaxoSmithKline Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)
- 11.6.5 GlaxoSmithKline Recent Developments
- 11.7 Novartis
  - 11.7.1 Novartis Company Details
  - 11.7.2 Novartis Business Overview
  - 11.7.3 Novartis APOL1 Mediated Kidney Disease Introduction
  - 11.7.4 Novartis Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)
  - 11.7.5 Novartis Recent Developments
- 11.8 Teva Pharmaceuticals
  - 11.8.1 Teva Pharmaceuticals Company Details
  - 11.8.2 Teva Pharmaceuticals Business Overview
  - 11.8.3 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
  - 11.8.4 Teva Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2018-2023)
  - 11.8.5 Teva Pharmaceuticals Recent Developments

## **12 ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **13 APPENDIX**

- 13.1 Research Methodology
  - 13.1.1 Methodology/Research Approach
  - 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details

## List Of Tables

### LIST OF TABLES

Table 1. Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Type (US\$ Million), 2018 VS 2022 VS 2029

Table 2. Key Players of Small Molecule

Table 3. Key Players of Gene Modification

Table 4. Key Players of Nucleic Acid Therapies

Table 5. Key Players of Others

Table 6. Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Application (US\$ Million), 2018 VS 2022 VS 2029

Table 7. Global APOL1 Mediated Kidney Disease Market Size Growth Rate (CAGR) by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 8. Global APOL1 Mediated Kidney Disease Market Size by Region (2018-2023) & (US\$ Million)

Table 9. Global APOL1 Mediated Kidney Disease Market Share by Region (2018-2023)

Table 10. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 11. Global APOL1 Mediated Kidney Disease Market Share by Region (2024-2029)

Table 12. APOL1 Mediated Kidney Disease Market Trends

Table 13. APOL1 Mediated Kidney Disease Market Drivers

Table 14. APOL1 Mediated Kidney Disease Market Challenges

Table 15. APOL1 Mediated Kidney Disease Market Restraints

Table 16. Global APOL1 Mediated Kidney Disease Revenue by Players (2018-2023) & (US\$ Million)

Table 17. Global APOL1 Mediated Kidney Disease Revenue Share by Players (2018-2023)

Table 18. Global Top APOL1 Mediated Kidney Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in APOL1 Mediated Kidney Disease as of 2022)

Table 19. Global APOL1 Mediated Kidney Disease Industry Ranking 2021 VS 2022 VS 2023

Table 20. Global 5 Largest Players Market Share by APOL1 Mediated Kidney Disease Revenue (CR5 and HHI) & (2018-2023)

Table 21. Global Key Players of APOL1 Mediated Kidney Disease, Headquarters and Area Served

Table 22. Global Key Players of APOL1 Mediated Kidney Disease, Product and

Application

Table 23. Global Key Players of APOL1 Mediated Kidney Disease, Product and Application

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global APOL1 Mediated Kidney Disease Market Size by Type (2018-2023) & (US\$ Million)

Table 26. Global APOL1 Mediated Kidney Disease Revenue Market Share by Type (2018-2023)

Table 27. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 28. Global APOL1 Mediated Kidney Disease Revenue Market Share by Type (2024-2029)

Table 29. Global APOL1 Mediated Kidney Disease Market Size by Application (2018-2023) & (US\$ Million)

Table 30. Global APOL1 Mediated Kidney Disease Revenue Share by Application (2018-2023)

Table 31. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 32. Global APOL1 Mediated Kidney Disease Revenue Share by Application (2024-2029)

Table 33. North America APOL1 Mediated Kidney Disease Market Size by Type (2018-2023) & (US\$ Million)

Table 34. North America APOL1 Mediated Kidney Disease Market Size by Type (2024-2029) & (US\$ Million)

Table 35. North America APOL1 Mediated Kidney Disease Market Size by Application (2018-2023) & (US\$ Million)

Table 36. North America APOL1 Mediated Kidney Disease Market Size by Application (2024-2029) & (US\$ Million)

Table 37. North America APOL1 Mediated Kidney Disease Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 38. North America APOL1 Mediated Kidney Disease Market Size by Country (2018-2023) & (US\$ Million)

Table 39. North America APOL1 Mediated Kidney Disease Market Size by Country (2024-2029) & (US\$ Million)

Table 40. Europe APOL1 Mediated Kidney Disease Market Size by Type (2018-2023) & (US\$ Million)

Table 41. Europe APOL1 Mediated Kidney Disease Market Size by Type (2024-2029) & (US\$ Million)

Table 42. Europe APOL1 Mediated Kidney Disease Market Size by Application



(2018-2023) & (US\$ Million)

Table 43. Europe APOL1 Mediated Kidney Disease Market Size by Application

(2024-2029) & (US\$ Million)

Table 44. Europe APOL1 Mediated Kidney Disease Growth Rate (CAGR) by Country

(US\$ Million): 2018 VS 2022 VS 2029

Table 45. Europe APOL1 Mediated Kidney Disease Market Size by Country

(2018-2023) & (US\$ Million)

Table 46. Europe APOL1 Mediated Kidney Disease Market Size by Country

(2024-2029) & (US\$ Million)

Table 47. China APOL1 Mediated Kidney Disease Market Size by Type (2018-2023) &

(US\$ Million)

Table 48. China APOL1 Mediated Kidney Disease Market Size by Type (2024-2029) &

(US\$ Million)

Table 49. China APOL1 Mediated Kidney Disease Market Size by Application

(2018-2023) & (US\$ Million)

Table 50. China APOL1 Mediated Kidney Disease Market Size by Application

(2024-2029) & (US\$ Million)

Table 51. Asia APOL1 Mediated Kidney Disease Market Size by Type (2018-2023) &

(US\$ Million)

Table 52. Asia APOL1 Mediated Kidney Disease Market Size by Type (2024-2029) &

(US\$ Million)

Table 53. Asia APOL1 Mediated Kidney Disease Market Size by Application

(2018-2023) & (US\$ Million)

Table 54. Asia APOL1 Mediated Kidney Disease Market Size by Application

(2024-2029) & (US\$ Million)

Table 55. Asia APOL1 Mediated Kidney Disease Growth Rate (CAGR) by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 56. Asia APOL1 Mediated Kidney Disease Market Size by Region (2018-2023) & (US\$ Million)

Table 57. Asia APOL1 Mediated Kidney Disease Market Size by Region (2024-2029) & (US\$ Million)

Table 58. Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Type (2018-2023) & (US\$ Million)

Table 59. Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Type (2024-2029) & (US\$ Million)

Table 60. Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Application (2018-2023) & (US\$ Million)

Table 61. Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Application (2024-2029) & (US\$ Million)

Table 62. Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 63. Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Country (2018-2023) & (US\$ Million)

Table 64. Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size by Country (2024-2029) & (US\$ Million)

Table 65. Vertex Pharmaceuticals Company Details

Table 66. Vertex Pharmaceuticals Business Overview

Table 67. Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Product

Table 68. Vertex Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2018-2023) & (US\$ Million)

Table 69. Vertex Pharmaceuticals Recent Developments

Table 70. Ionis Pharmaceuticals Company Details

Table 71. Ionis Pharmaceuticals Business Overview

Table 72. Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Product

Table 73. Ionis Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2018-2023) & (US\$ Million)

Table 74. Ionis Pharmaceuticals Recent Developments

Table 75. Traverre Therapeutics Company Details

Table 76. Traverre Therapeutics Business Overview

Table 77. Traverre Therapeutics APOL1 Mediated Kidney Disease Product

Table 78. Traverre Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2018-2023) & (US\$ Million)

Table 79. Traverre Therapeutics Recent Developments

Table 80. ChemoCentryx Company Details

Table 81. ChemoCentryx Business Overview

Table 82. ChemoCentryx APOL1 Mediated Kidney Disease Product

Table 83. ChemoCentryx Revenue in APOL1 Mediated Kidney Disease Business (2018-2023) & (US\$ Million)

Table 84. ChemoCentryx Recent Developments

Table 85. ZyVersa Therapeutics Company Details

Table 86. ZyVersa Therapeutics Business Overview

Table 87. ZyVersa Therapeutics APOL1 Mediated Kidney Disease Product

Table 88. ZyVersa Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2018-2023) & (US\$ Million)

Table 89. ZyVersa Therapeutics Recent Developments

Table 90. GlaxoSmithKline Company Details

Table 91. GlaxoSmithKline Business Overview

Table 92. GlaxoSmithKline APOL1 Mediated Kidney Disease Product



Table 93. GlaxoSmithKline Revenue in APOL1 Mediated Kidney Disease Business (2018-2023) & (US\$ Million)

Table 94. GlaxoSmithKline Recent Developments

Table 95. Novartis Company Details

Table 96. Novartis Business Overview

Table 97. Novartis APOL1 Mediated Kidney Disease Product

Table 98. Novartis Revenue in APOL1 Mediated Kidney Disease Business (2018-2023) & (US\$ Million)

Table 99. Novartis Recent Developments

Table 100. Teva Pharmaceuticals Company Details

Table 101. Teva Pharmaceuticals Business Overview

Table 102. Teva Pharmaceuticals APOL1 Mediated Kidney Disease Product

Table 103. Teva Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2018-2023) & (US\$ Million)

Table 104. Teva Pharmaceuticals Recent Developments

Table 105. Research Programs/Design for This Report

Table 106. Key Data Information from Secondary Sources

Table 107. Key Data Information from Primary Sources

## List Of Figures

### LIST OF FIGURES

Figure 1. Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US\$ Million)

Figure 2. Global APOL1 Mediated Kidney Disease Market Share by Type: 2022 VS 2029

Figure 3. Small Molecule Features

Figure 4. Gene Modification Features

Figure 5. Nucleic Acid Therapies Features

Figure 6. Others Features

Figure 7. Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US\$ Million)

Figure 8. Global APOL1 Mediated Kidney Disease Market Share by Application: 2022 VS 2029

Figure 9. Chronic Kidney Disease Case Studies

Figure 10. End Stage Kidney Disease Case Studies

Figure 11. APOL1 Mediated Kidney Disease Report Years Considered

Figure 12. Global APOL1 Mediated Kidney Disease Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 13. Global APOL1 Mediated Kidney Disease Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 14. Global APOL1 Mediated Kidney Disease Market Share by Region: 2022 VS 2029

Figure 15. Global APOL1 Mediated Kidney Disease Market Share by Players in 2022

Figure 16. Global Top APOL1 Mediated Kidney Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in APOL1 Mediated Kidney Disease as of 2022)

Figure 17. The Top 10 and 5 Players Market Share by APOL1 Mediated Kidney Disease Revenue in 2022

Figure 18. North America APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 19. North America APOL1 Mediated Kidney Disease Market Share by Type (2018-2029)

Figure 20. North America APOL1 Mediated Kidney Disease Market Share by Application (2018-2029)

Figure 21. North America APOL1 Mediated Kidney Disease Market Share by Country (2018-2029)

Figure 22. United States APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. Canada APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Europe APOL1 Mediated Kidney Disease Market Size YoY (2018-2029) & (US\$ Million)

Figure 25. Europe APOL1 Mediated Kidney Disease Market Share by Type (2018-2029)

Figure 26. Europe APOL1 Mediated Kidney Disease Market Share by Application (2018-2029)

Figure 27. Europe APOL1 Mediated Kidney Disease Market Share by Country (2018-2029)

Figure 28. Germany APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. France APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. U.K. APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Italy APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Russia APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Nordic Countries APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. China APOL1 Mediated Kidney Disease Market Size YoY (2018-2029) & (US\$ Million)

Figure 35. China APOL1 Mediated Kidney Disease Market Share by Type (2018-2029)

Figure 36. China APOL1 Mediated Kidney Disease Market Share by Application (2018-2029)

Figure 37. Asia APOL1 Mediated Kidney Disease Market Size YoY (2018-2029) & (US\$ Million)

Figure 38. Asia APOL1 Mediated Kidney Disease Market Share by Type (2018-2029)

Figure 39. Asia APOL1 Mediated Kidney Disease Market Share by Application (2018-2029)

Figure 40. Asia APOL1 Mediated Kidney Disease Market Share by Region (2018-2029)

Figure 41. Japan APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. South Korea APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. China Taiwan APOL1 Mediated Kidney Disease Market Size YoY Growth

(2018-2029) & (US\$ Million)

Figure 44. Southeast Asia APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. India APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Australia APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Size YoY (2018-2029) & (US\$ Million)

Figure 48. Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Share by Type (2018-2029)

Figure 49. Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Share by Application (2018-2029)

Figure 50. Middle East, Africa, and Latin America APOL1 Mediated Kidney Disease Market Share by Country (2018-2029)

Figure 51. Brazil APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 52. Mexico APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 53. Turkey APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 54. Saudi Arabia APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 55. Israel APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 56. GCC Countries APOL1 Mediated Kidney Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 57. Vertex Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2018-2023)

Figure 58. Ionis Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2018-2023)

Figure 59. Travere Therapeutics Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2018-2023)

Figure 60. ChemoCentryx Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2018-2023)

Figure 61. ZyVersa Therapeutics Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2018-2023)

Figure 62. GlaxoSmithKline Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2018-2023)

Figure 63. Novartis Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2018-2023)

Figure 64. Teva Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2018-2023)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

## I would like to order

Product name: Global APOL1 Mediated Kidney Disease Market Insights, Forecast to 2029

Product link: <https://marketpublishers.com/r/G1DF96B43EBBEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1DF96B43EBBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970